Clinical trial · Interventional
Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN'S DISEASE
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow or peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy followed by bone marrow or peripheral stem cell transplantation in treating patients with relapsed or refractory Hodgkin's lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| autologous bone marrow transplantation | Procedure | — | UNRESOLVED |
| bone marrow ablation with stem cell support | Procedure | — | UNRESOLVED |
| cisplatin | Drug | Cisplatin | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| etoposide | Drug | Etoposide | ALIAS |
| peripheral blood stem cell transplantation | Procedure | — | UNRESOLVED |
| radiation therapy | Radiation | — | UNRESOLVED |
| syngeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 70 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically proven stage I-IV Hodgkin's lymphoma
* Must have refractory or relapsed disease, defined by 1 of the following:
* Failure to achieve a complete remission (CR) after 4 courses of conventional-dose front-line chemotherapy
* Disease in second or greater remission
* Patients should be encouraged to undergo transplantation prior to a third salvage regimen
* Patients previously treated with multiple regimens considered on a case-by-case basis
* No chemoresistant disease, defined as active progression with tumor growth greater than 25% by volume during first-line chemotherapy
* Patients who respond to second-line chemotherapy may be eligible
* Stable residual masses after conventional-dose chemotherapy not considered treatment failures
* Active (refractory or relapsed) disease must be proven histologically or documented by gallium nitrate uptake
* Syngeneic marrow transplantation offered to patients with consenting identical twin donor
* No CNS involvement by lymphoma
PATIENT CHARACTERISTICS:
Age:
* 15 to 60 (selected patients up to age 70 may be eligible)
Performance status:
* ECOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* WBC greater than 4,000/mm\^3
* Absolute neutrophil count greater than 2,000/mm\^3
* Platelet count greater than 100,000/mm\^3
Hepatic:
* Bilirubin less than 2.0 mg/dL
* SGOT and SGPT less than 2 times upper limit of normal
* Albumin greater than 3.0 g/dL
Renal:
* Must meet 1 of the following criteria:
* Creatinine less than 1.8 mg/dL
* Creatinine clearance greater than 60 mL/min
* BUN less than 20 mg/dL
Cardiovascular:
* Left ventricular ejection fraction at least 50%
Pulmonary:
* DLCO, FEV\_1, and FVC greater than 50% of predicted OR
* Resting pO\_2 greater than 70 mm Hg on room air
Other:
* HIV negative
* No severe neurologic or emotional disorders
* No active infection
* No other disease that would limit life expectancy
* Not pregnant
* Fertile patients must use effective contraception
* Adequate psychosocial support required
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* See Disease Characteristics
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specifiedReferences
Publications (0)
Data not yet available